Business Context and Reporting Period
This Form 8-K was filed by Artelo Biosciences, Inc. on August 24, 2022. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Stock Market, LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event notification and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resolution of a compliance issue with Nasdaq Listing Rule 5550(a)(2). On August 24, 2022, the Company received formal notification from Nasdaq confirming it had regained compliance with the minimum bid price requirement of at least $1.00 per share. Consequently, the matter regarding the potential delisting or non-compliance is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the bid price compliance matter.
Investor Verification Checklist
- Verify the current trading price of Artelo Biosciences common stock (Symbol: ARTL) to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the status of the company's warrants (Symbol: ARTLW) on Nasdaq.
- Review subsequent filings to ensure no new compliance notices have been issued by Nasdaq.